Reviewing Stagezero Life Sciences (OTCMKTS:SZLSF) and Senestech (NASDAQ:SNES)

Senestech (NASDAQ:SNES) and Stagezero Life Sciences (OTCMKTS:SZLSF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares Senestech and Stagezero Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Senestech	-253.54%	-98.35%	-73.17%
Stagezero Life Sciences	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Senestech and Stagezero Life Sciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senestech	1	1	0	1	2.33
Stagezero Life Sciences	0	0	0	0	0.00

Earnings and Valuation

This table compares Senestech and Stagezero Life Sciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senestech	$1.86 million	5.87	-$6.18 million	($3.65)	-0.57
Stagezero Life Sciences	N/A	N/A	N/A	($0.01)	-0.05

Stagezero Life Sciences has lower revenue, but higher earnings than Senestech. Senestech is trading at a lower price-to-earnings ratio than Stagezero Life Sciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

5.2% of Senestech shares are owned by institutional investors. 5.3% of Senestech shares are owned by insiders. Comparatively, 2.5% of Stagezero Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Senestech has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Stagezero Life Sciences has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500.

Summary

Senestech beats Stagezero Life Sciences on 6 of the 11 factors compared between the two stocks.

About Senestech

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.

About Stagezero Life Sciences

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman’s risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.